ZYUS Life Sciences

Treating Chronic Pain Without Opioids

About this Event

Chronic pain affects 1.6 billion people globally, including 50 million U.S. adults. Current pain treatments are limited, over-the-counter drugs like ibuprofen causing side effects unsuitable for long-term use, and opioids are still a huge problem. More than 9 million people misused opioids last year resulting in 100,000 deaths (NIH), costings the U.S. economy over $1 trillion annually (Forbes, 2022).

There is still an urgent need for safer, alternative treatments.

ZYUS Life Sciences (CVE: ZYUS) is creating a world where chronic pain is managed effectively, safely, and compassionately. By harnessing the therapeutic potential of cannabinoids, ZYUS is developing an innovative pipeline of non-opioid therapies to improve patients’ lives.

Their lead product, Trichomylin® softgel capsules, is a proprietary formulation containing cannabichromene (CBC), a newly discovered, non-psychoactive molecule that shows significant potential for effective pain relief.

Phase 1 trials confirmed the safety and tolerability of Trichomylin® softgel capsules, with no serious adverse events reported. ZYUS is preparing for Phase 2 clinical trials later this year in Canada for patients with advanced cancer experiencing moderate to severe pain.

Register now to watch our Fireside Chat with ZYUS CEO, Brent Zettl and Dr. Hance Clarke, director of Pain Services and the medical director of the Pain Research Unit at the Toronto General Hospital. They will discuss new and innovative approaches to creating non-addictive treatments for the $50B chronic pain market.

Video On Demand

– Recorded

March 5

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.